Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre “real-world” experience

References

• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.
   PubMed Web of Science ®Google Scholar
• Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011;25:110–120.
   PubMed Web of Science ®Google Scholar
• Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006;24: 2576–2582.
   PubMed Web of Science ®Google Scholar
• Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions. Oncologist 2008;13(Suppl.): S27–S32.
   PubMed Web of Science ®Google Scholar
• Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes 2009;7:81.
   PubMed Web of Science ®Google Scholar
• Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012;26: 1286–1292.
   PubMed Web of Science ®Google Scholar
• List AF. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control 2008; 15(Suppl.):S29–S39.
   PubMedGoogle Scholar
• Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607–3613.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Park S, Brechignac S, et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era: the GFM experience with EPO and thalidomide. Leukemia Res 2008;32:1049–1053.
   PubMed Web of Science ®Google Scholar
• Sanna A, Latagliata R, Gioia D, et al. Treatment with erythropoietic stimulating agents in IPSS lower risk MDS: outcome comparison between 5q- and non 5q-MDS cases. Blood 2011;118:(Suppl.). Abstract 2799.
   Google Scholar
• List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–557.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765–3776.
   PubMed Web of Science ®Google Scholar
• Le Bras F, Sebert M, Kelaidi C, et al. Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion – the GFM experience. Leukemia Res 2011;35:1444–1448.
   PubMed Web of Science ®Google Scholar
• Mecucci C, Roncadori A, La Starza R, et al. Lenalidomide in myelodysplastic syndromes with 5q deletion. Results from the Italian National Cancer Registry. Blood 2012;120:(Suppl.). Abstract 3850.
   Google Scholar
• Oliva EN, Cuzzola M, Aloe Spiriti MA, et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol 2013;92:25–32.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Gore SD, McNally DL, et al. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer 2013;119:3870–3878.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Withdrawal Assessment Report For Lenalidomide Celgene Europe. 2008; Document reference: EMEA/CHMP/249329/2008
   Google Scholar
• Ades L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica 2012;97:213–218.
   Google Scholar
• Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 2013;27:1072–1079.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013;122:2943–2964.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207–214.
   PubMed Web of Science ®Google Scholar
• Gross E, Kiechle M, Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Meth 2001;47:73–81.
   PubMedGoogle Scholar
• Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589–2597.
   PubMed Web of Science ®Google Scholar
• Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 2011;29:3185–3193.
   PubMed Web of Science ®Google Scholar
• Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012;26:1458–1461.
   PubMed Web of Science ®Google Scholar
• Mallo M, Del Rey M, Ibanez M, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol 2013;162:74–86.
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Mittelman M, et al. Outcomes in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol 2014;93:429–438.
   PubMed Web of Science ®Google Scholar
• Gohring G, Giagounidis A, Busche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010;89: 365–374.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Swern AS, Giagounidis A, et al. Association of cytogenetic response with RBC transfusion-independence and AML-free survival in lenalidomide-treated patients with IPSS low-/int-1-risk MDS with del(5q). Blood 2013;122:(Suppl.). Abstract 390.
   Google Scholar
• List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia 2014;28: 1033–1040.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160:660–672.
   PubMed Web of Science ®Google Scholar
• Saft L, Karimi M, Ghaderi M, et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica 2014;99: 1041–1049.
   PubMed Web of Science ®Google Scholar
• Jadersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009; 94:1762–1766.
   PubMed Web of Science ®Google Scholar
• Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011;29:1971–1979.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008;26: 5943–5949.
   PubMed Web of Science ®Google Scholar